Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial

INTRODUCTION: There are no determined treatment agents for severe COVID-19. It is suggested that methylprednisolone, as an immunosuppressive treatment, can reduce the inflammation of the respiratory system in COVID-19 patients. METHODS: We conducted a single-blind, randomised controlled clinical tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Edalatifard, Maryam, Akhtari, Maryam, Salehi, Mohammadreza, Naderi, Zohre, Jamshidi, Ahmadreza, Mostafaei, Shayan, Najafizadeh, Seyed Reza, Farhadi, Elham, Jalili, Nooshin, Esfahani, Masoud, Rahimi, Besharat, Kazemzadeh, Hossein, Mahmoodi Aliabadi, Maedeh, Ghazanfari, Tooba, Sattarian, Mohammadreza, Ebrahimi Louyeh, Hourvash, Raeeskarami, Seyed Reza, Jamalimoghadamsiahkali, Saeidreza, Khajavirad, Nasim, Mahmoudi, Mahdi, Rostamian, Abdolrahman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758541/
https://www.ncbi.nlm.nih.gov/pubmed/32943404
http://dx.doi.org/10.1183/13993003.02808-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758541/
https://www.ncbi.nlm.nih.gov/pubmed/32943404
http://dx.doi.org/10.1183/13993003.02808-2020

Ejemplares similares